Segments (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Summary of Information by Reportable Segment

Segment Adjusted EBITDA by reportable segment was as follows:

	Year Ended December 31, 2024
	Biopharmaceuticals		Exemplar		Total
Revenues from external customers/Total segment revenues	$	—	$	3,925	$	3,925
Less:
Salaries, benefits and other payroll expenses, including severance cost	(43,363)		(2,879)
Rent and Utilities	(3,195)		(706)
Capital Expenditures	(8,477)		(47)
Other Segment Adjusted EBITDA	(27,252)		(1,222)
Segment Adjusted EBITDA	$	(82,287)	$	(929)	$	(83,216)

	Year Ended December 31, 2023
	Biopharmaceuticals		Exemplar		Total
Revenues from external customers/Total segment revenues	$	75	$	6,150	$	6,225
Less:
Salaries, benefits and other payroll expenses	(40,276)		(3,774)
Rent and Utilities	(2,854)		(801)
Capital Expenditures	(1,251)		(187)
Other Segment Adjusted EBITDA	(31,033)		(2,114)
Segment Adjusted EBITDA	$	(75,339)	$	(726)	$	(76,065)

	Year Ended December 31, 2022
	Biopharmaceuticals		Exemplar		Total
Revenues from external customers/Total segment revenues	$	14,894	$	12,015	$	26,909
Less:
Salaries, benefits and other payroll expenses	(37,624)		(3,771)
Rent and Utilities	(4,093)		(745)
Capital Expenditures	(1,254)		(141)
Other Segment Adjusted EBITDA	(49,465)		(2,361)
Segment Adjusted EBITDA	$	(77,542)	$	4,997	$	(72,545)

Goodwill by reportable segment was as follows:

	Biopharmaceuticals		Exemplar		Total
Goodwill
Balances at December 31, 2022	$	16,847	$	20,076	$	36,923
Impairments	—		(10,390)		$	(10,390)
Foreign currency translation adjustments	79		—		79
Balances at December 31, 2023	16,926		9,686		26,612
Foreign currency translation adjustments	(64)		—		(64)
Impairments	(1,630)		(5,779)		(7,409)
Balances at December 31, 2024	$	15,232	$	3,907	$	19,139

Summary of Reconciliation of Operating Profit (Loss) from Segments to Consolidated

The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss from continuing operations before income taxes:

	Year Ended December 31,
	2024		2023		2022
Segment Adjusted EBITDA for reportable segments	$	(83,216)	$	(76,065)	$	(72,545)
Remove cash paid for capital expenditures net of proceeds from sale of assets	8,524		1,438		1,395
Interest Income	1,418		3,237		133
Add recognition of previously deferred revenue associated with upfront and milestone payments	—		—		14,561
Other expenses:
Interest expense	(6)		(468)		(6,774)
Depreciation and amortization	(4,526)		(6,668)		(7,191)
Gain (loss) from disposals of assets	2		72		—
Impairment losses	(40,324)		(10,835)		(1,120)
Stock-based compensation expense	(9,471)		(9,888)		(10,197)
Adjustment related to accrued bonuses paid in equity awards	3,039		3,361		1,698
Equity in net income (loss) of affiliates	—		—		862
Shares issued for payment of services	(553)		(545)		(575)
Other	—		(1)		(107)
Reversal of cumulative foreign translation losses	(2,915)		—		—
Eliminations	—		—		(106)
Consolidated loss from continuing operations before income taxes	$	(128,028)	$	(96,362)	$	(79,966)